Therefore, we currently point out that utilizing in vitro APC activation with MuSyC analysis/optimization and translating that to in vivo is a sufficient and cost-effective approach for combining adjuvants, as demonstrated with the in vitro derived MuSyC-dose, leading to a synergistic decrease in tumor volume and modulation of the tumor microenvironment. Here, APC is linked to neoplasm.